Covid-19 Vaccines in Development and Use

by Andrii Buvailo , Irina Bilous  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

   442    Comments 0
Topics: Coronavirus   

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is a positive sense, single-stranded RNA beta coronavirus, a member of Beta-CoV lineage B (subgenus Sarbecovirus).

Here is a list of approved vaccines and vaccines in development. This data is for informational purposes only, not medical advice. 

Table 1. Vaccines In Use

Candidate Status/clinical trials Sponsor/Producer Number of countries vaccine being used Efficacy, %
Vaxzevria
(CoviShield)
AZD1222 (ChAdOx1)
Viral vector
Phase III
NCT04516746
NCT04540393
Phase I/II
NCT04568031
NCT04686773
AstraZeneca, University of Oxford 184 63.0
https://www.who.int/news-room/feature-stories/detail/the-oxford-astrazeneca-covid-19-vaccine-what-you-need-to-know
Comirnaty
BNT162b2
mRNA vaccine
Phase III
NCT04713553(completed)
NCT04848584
BioNTech in collaboration with Pfizer 124 95.0
https://www.who.int/ru/news-room/feature-stories/detail/who-can-take-the-pfizer-biontech-covid-19--vaccine
Spikevax
mRNA-1273
mRNA vaccine
Phase IIINCT04860297Phase IINCT04847050Phase I NCT04283461
NCT04785144
NIAID in collaboration with ModernaTherapeutics 71 94.1
https://www.who.int/publications/i/item/interim-recommendations-for-use-of-the-moderna-mrna-1273-vaccine-against-covid-19
BBIBP-CorV
Inactivated virus
Phase I/II
NCT04993560
Sinopharm-Beijing 68 86.0
https://gulfnews.com/uae/health/uae-ministry-of-health-announces-86-per-cent-vaccine-efficacy-1.1607490555571
JNJ-78436735 (Ad26.COV2.S)Viral vector Phase III
NCT04505722
Johnson & Johnson 48 66.9
https://www.who.int/news-room/feature-stories/detail/the-j-j-covid-19-vaccine-what-you-need-to-know
Sputnik V
Gam-COVID-Vac,
Gam-COVID-VacLyo
Viral vector
Phase I/II clinical trial in Russia
NCT04436471
NCT04437875
Phase III
NCT04530396
Gamaleya Research Institute 46 94.0
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00234-8/fulltext
CoronaVac
Inactivated virus
Phase III clinical trial in BrazilNCT04456595
Phase IV
NCT04789356
Sinovac, ButantanInstitute 41 51
Covaxin
BBV-152
Inactivated virus
Phase I/II
NCT04471519
Phase III
NCT04641481
Bharat Biotech 7 -
Recombinant Coronavirus vaccine Phase II
NCT04313127
NCT04341389
CanSinoBiologics Inc. 5 -

 

Table 2. Vaccines in development

Candidate Vaccine type Status/clinical trials Sponsor/Producer
AdimrSC-2f protein subunit Phase I Clinical Trials in TaiwanNCT04522089 Adimmune Corporation
siRNA RNA Preclinical development Alnylam and Vir Biotechnology
ZF2001 protein subunit Phase III AnhuiZhifei Longcom
ARCT-021 RNA Phase II NCT04728347 Arcturus Therapeutics
BBV-154 viral vector Phase I NCT04751682 Bharat Biotech
SCB-2019 protein subunit Phase I NCT04932824 Clover Biopharmaceuticals
COVI-VAC live-attenuated Phase I NCT04619628 Codagenix
UB-612 multitope peptide-based vaccine (MPV) Phase I NCT04545749 COVAXX, United Biomedical
CVnCoV mRNA Phase III NCT04860258 Curevac
Vaccine adjuvant CpG1018   Phase III NCT05012787 Dynavax Technologies Corp
Coronavirus vaccine   Preclinical development Geovax
Vaccine adjuvant   Preclinical development
(adjuvant to S-Trimer vaccine)
GlaxoSmithKline
Self-assembling vaccine (SAV)   Preclinical development HaloVax (Hoth Therapeutics + Voltron Therapeutics)
Coronavirus vaccine   Preclinical development Heat Biologics Inc.
INO-4800
DNA-based vaccine
DNA Phase I/II Clinical Trials NCT04447781
NCT04336410
Inovio Pharmaceuticals
ReCoV protein subunit Phase I Jiangsu Rec-Biotechnology Co Ltd
MVC-COV1901 protein subunit Phase I/II NCT04487210 NCT04951388 Medigen
mRNA-1283 mRNA Phase I NCT04813796 NIAID in collaboration with Moderna Therapeutics
NVX-CoV2373
Coronavirus vaccine
protein subunit Preclinical development Novavax Inc
CoVepiT (OSE13E) protein subunit Phase I NCT04885361 OSE Immunotherapeutics
TAK-019 (Novavax formulation) protein subunit Phase I/II NCT04712110 Takeda
adjuvanted recombinant protein vaccine   Phase II/III NCT04762680 Sanofi Pasteur with GSK

Topics: Coronavirus   

Share this:              

You may also be interested to read:

 

Comments:

There are no comments yet. You can be the first.

Leave a Reply

Your email address will not be published. Required fields are marked *